Patients lose access to affordable obesity drug alternatives

Patients are facing uncertainty as the availability of a cheaper obesity drug, tirzepatide, is coming to an end. Compounding pharmacies, which made these versions, must stop production by Wednesday, as the FDA declared the shortage of Eli Lilly's Zepbound over. Christina and Jackson Agar from Minnesota have benefited from using tirzepatide, leading to significant weight loss and improvements in their health. However, they did not expect their supply to suddenly be cut off. Many patients are expressing worry and frustration about the upcoming changes. In Arizona, Margot Carmichael is struggling with the news. She was hopeful that the compounded drugs would remain available. As the deadline approaches, some patients are confused by conflicting messages from telehealth companies regarding whether they will still have access to the medication. Many patients have taken matters into their own hands by stocking up on the drug, concerned about the future. However, not everyone can afford the high costs of Zepbound from Eli Lilly, with prices reaching $1,000 or more each month without insurance. Patients are worried about their options moving forward. Some have considered turning to an unofficial market for the drug, but others, like Jackson Agar, are hesitant to take such risks. They highlight the need for safe and affordable solutions as their treatment options dwindle.